Drugs / RBX7455
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04139993 | Aug 2020 → Jan 2023 | breast adenocarcinoma, female breast carcinoma, invasive breast carcinoma, triple-negative breast carcinoma | Mayo Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03378167 | Dec 2018 → Sep 2023 | Crohn disease, colitis | McMaster Children's Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04155099 | Mar 2021 → Jul 2023 | cirrhosis of liver, hepatic encephalopathy | Ochsner Health System | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02981316 Comparator | Nov 2016 → Jul 2020 | Clostridium difficile colitis | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBX7455 | “Fecal microbiota enema (RBX2660) infused via colonoscope x 1 + oral microbiota capsules (RBX7455) x 6 weeks.” NCT03378167 ↗ |
| Action | Restore | “may restore the normal balance of microorganisms in the intestines” NCT04139993 ↗ |
| Modality | Other / unclassified | “investigational live biotherapeutic” PMID 32966574 ↗ Oct 2021 |
| Route | Oral | “orally administered investigational live biotherapeutic” PMID 32966574 ↗ Oct 2021 |